This comprehensive approach enables researchers to identify critical transition points—for instance, whether pTau231 peak concentrations drive subsequent tau pathological deposition—and threshold effects where specific protein concentrations might predict Alzheimer’s disease or CTE risk 5–10 years post-injury (8). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.